Investigational Treatments for COVID‐19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions-Reference-Cited by-同舟云学术

Investigational Treatments for COVID‐19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions

Published:2021-02 Issue:2 Volume:10 Page:100-107
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Varshneya Meera¹,Irurzun-Arana Itziar¹,Campana Chiara¹,Dariolli Rafael¹,Gutierrez Amy¹,Pullinger Taylor K.¹,Sobie Eric A.¹

Affiliation:

1. Department of Pharmacological Sciences and Graduate School of Biomedical Sciences Icahn School of Medicine at Mount Sinai New York New York USA

Funder

National Institutes of Health

National Science Foundation

Food and Drug Administration

National Institute of General Medical Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12573

Reference34 articles.

1. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

2. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus

3. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

4. The COVIRL‐001 trial: a multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non‐critical, SARS‐CoV‐2 PCR‐positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: a structured summary of a study protocol for a randomised controlled trial;Feeney E.;Trials,2020

5. An evaluation of co‐use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: a pharmacoepidemiological study to inform use during the COVID19 pandemic;Vouri S.M.;Res. Social Adm. Pharm.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity;Computer Methods and Programs in Biomedicine;2023-12

2. HPC Framework for Performing in Silico Trials Using a 3D Virtual Human Cardiac Population as Means to Assess Drug-Induced Arrhythmic Risk;Methods in Molecular Biology;2023-09-14

3. Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA);Frontiers in Pharmacology;2023-08-15

4. The potential role of SARS‐CoV‐2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread;Immunity, Inflammation and Disease;2023-03

5. In silico assessment on TdP risks of drug combinations under CiPA paradigm;Scientific Reports;2023-02-20